|
|
Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study
Sébastien Dharancy
,
Audrey Coilly
,
Claire Fougerou-Leurent
,
Christophe Duvoux
,
Nassim Kamar
et al.
Journal articles
hal-01640061v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence Prophylaxis makes the difference
Lina Mouna
,
Emilie Rossignol
,
Mariagrazia Tateo
,
Audrey Coilly
,
Jean-Charles Duclos-Vallee
et al.
Journal articles
hal-02120675v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study
Audrey Coilly
,
Claire Fougerou-Leurent
,
Victor De Ledinghen
,
Pauline Houssel-Debry
,
Christophe Duvoux
et al.
Journal articles
hal-01395132v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment a prospective cohort study
Fabrice Carrat
,
Hélène Fontaine
,
Céline Dorival
,
Mélanie Simony
,
Alpha Diallo
et al.
Journal articles
hal-02050395v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients
Stanislas Pol
,
Marc Bourlière
,
Sandy Lucier
,
Christophe Hézode
,
Céline Dorival
et al.
Journal articles
hal-01435007v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
No evidence of hepatitis B virus reactivation among liver transplant recipients treated with interferon- free regimens for hepatitis C virus recurrence (ANRS CO23 CUPILT Cohort)
Lina Mouna
,
Emilie Rossignol
,
Mariagrazia Tateo
,
Jean-Charles Duclos-Vallee
,
Christophe Duvoux
et al.
Hepatology, 2017, 66, pp.873A-874A
Journal articles
hal-01769634v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Marc Bourlière
,
Jean-Pierre Bronowicki
,
Victor de Ledinghen
,
Christophe Hézode
,
Fabien Zoulim
et al.
Journal articles
hal-01134440v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study
Laurent Lam
,
Hélène Fontaine
,
Marc Bourliere
,
Clovis Lusivika-Nzinga
,
Céline Dorival
et al.
Journal articles
hal-03224103v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study.
Pauline Houssel-Debry
,
Audrey Coilly
,
Claire Fougerou-Leurent
,
Caroline Jezequel
,
Christophe Duvoux
et al.
Hepatology, 2017, 63 (1 SUPP), pp.465A--465A
Journal articles
hal-01412958v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation
Pauline Houssel-Debry
,
Audrey Coilly
,
Claire Fougerou-Leurent
,
Caroline Jezequel
,
Christophe Duvoux
et al.
Journal articles
hal-01807755v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
Georges‐philippe Pageaux
,
Clovis Lusivika Nzinga
,
Nathalie Ganne
,
Didier Samuel
,
Céline Dorival
et al.
Journal articles
hal-03555553v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|